PASS syndrome is a rare inflammatory disease characterized by a chronic‐relapsing course of pyoderma gangrenosum, acne vulgaris, hidradenitis suppurativa, and spondyloarthritis, which is lack of any biological or genetic marker. Moreover, the optimal therapeutic management remains unclear. We herein describe a Yi Chinese man with PASS syndrome who was treated with secukinumab and showed a remarkable response with almost complete clinical improvement at the 2‐year follow‐up.

Lichen amyloidosis (LA) is the most common subtype of primary localized cutaneous amyloidosis (PLCA), usually manifested as hyperpigmented papules or plaques with intractable pruritus. 1 There is no